About Coya Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.coyatherapeutics.com/
Frequently Asked Questions
What is the 52-week range for COYA?
The 52-week high is $7.75 and the 52-week low is $3.71.
What is the P/E ratio for COYA?
The P/E ratio data is currently unavailable.
What is the dividend yield for COYA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -53.32%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -270.22%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.82.
Analyst Recommendation Trends
Wall Street analyst consensus for COYA over the last few months:
Latest COYA News
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON, September 15, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional participants continue to roll over into the active extension arm of the trialCOYA 302 has received FDA Fast Track
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
HOUSTON, September 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic app
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-04-09 | Pavao Mark H | +10,000 | - | - |
| 2026-01-22 | Grossman Fred | +140,041 | - | - |
| 2026-01-22 | Berman Howard | +15,257 | - | - |
| 2026-01-22 | Swaminathan Arun | +293,983 | - | - |
| 2026-01-22 | SNYDER DAVID S | +140,041 | - | - |
| 2026-01-02 | Villalobos Anabella | +10,000 | - | - |
| 2026-01-02 | Lee Ann | +10,000 | - | - |
| 2026-01-02 | Weinand Dieter | +10,000 | - | - |
| 2026-01-02 | GOLDSTEIN DOV A MD | +10,000 | - | - |
| 2026-01-02 | ROSS WILBUR L JR | +10,000 | - | - |